ReviewEuropean journal of microbiology & immunology2024
Phage therapy in prosthetic joint infections caused by Staphylococcus aureus - A literature review.
Review in European journal of microbiology & immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Article
- Phage therapy in revision arthroplasty: State of the art and application protocols.Arthroplasty (London, England) · 2026Review
- Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.Frontiers in immunology · 2026Review
- Substrate morphology modulates bacteriophage mobility and alters bactericidal potency.PloS one · 2026Article
- Article
- Old germs, novel approaches - A systematic review on pathogen distribution and therapeutic intervention strategies in periprosthetic joint infections.European journal of microbiology & immunology · 2025Review
- Phage Therapy for Bone and Joint Infections: Towards Clinical Translation.Antibiotics (Basel, Switzerland) · 2025Review
- Editorial: Bacteriophage therapy in orthopedics-Key questions and emerging answers.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2025Article
- Current Applications and the Future of Phage Therapy for Periprosthetic Joint Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Unconventional Therapies in Periprosthetic Joint Infections: Prevention and Treatment: A Narrative Review.Journal of clinical medicine · 2025Review
- Prosthetic Joint Infection Research Models in NZW Rabbits: Opportunities for Standardization-A Systematic Review.Journal of functional biomaterials · 2024Review
- Current status of clinical trials for phage therapy.Journal of medical microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prosthetic joint infections (PJIs) are dreaded arthroplasty complications often caused by Staphylococcus aureus. Due to methicillin-resistant S. aureus (MRSA) strains or biofilm formation, successful treatment remains difficult. Currently, two-stage revision surgery constitutes the gold standard therapy of PJIs, sometimes replaced or supplemented by debridement, antibiotics, and implant retention (DAIR). Given the dire consequences of therapeutic failure, bacteriophage therapy might be another treatment option. Here we provide a comprehensive literature review addressing the efficacy of phages applied against S. aureus as causative agent of PJIs. The included 17 publications had in common that the applied phages proved to be effective against various S. aureus isolates including MRSA even in biofilms. Experiments with mice, rats, rabbits, and moth larvae confirmed favorable features of phage preparations in PJI treatment in vivo; including its synergistic with antibiotics. Case reports of PJI patients unanimously described the bacterial eradication following, alongside other measures, intravenous and intra-articular phage administration. Generally, no major side effects occurred, but in some cases elevated liver transaminases were observed. To conclude, our review compiled promising evidence suggesting the safety and suitability of phage therapy as an adjuvant to DAIR in S. aureus PJIs, and thus, underscores the significance of further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.